详细介绍

学术任职

曾任广东省医学会肝癌综合治疗委员会副主任委员
Former Vice Chairperson of the Committee on Comprehensive Treatment of Liver Cancer, Guangdong Medical Association·

广东省医师协会脂肪肝与自身免疫性肝病组副组长
Guangdong Medical Doctors Association Former Deputy Head of the Fatty Liver and Autoimmune Liver Disease Group,

广东省医学会委员
Committee Member of the Guangdong Medical Association

擅长方向

对各种急、慢性病毒性肝炎、重型肝炎、酒精性肝病、肝硬化、脂肪肝等肝脏疾病及其他急性传染病、颅内感染、寄生虫病等，具有丰富的临床诊治经验
Has extensive clinical experience in the diagnosis and treatment of acute andchronic viral hepatitis, severe hepatitis, alcoholic liver disease, cirrhosis, fatty liverdisease, and other liver conditions, as well as acute infectious diseases, intracranialinfections, and parasitic diseases

主持及参与了多个国内及国际多中心病毒性肝炎新药的临床研究工作，是慢性乙肝、丙肝及肝硬化等抗病毒治疗方面国内有影响力的专家之一
Has led and participated in multiple domestic and international clinical trials of novelantiviral drugs for viral hepatitis and is recognized as a leading expert in China inantiviral therapy for chronic hepatitis B and C and related cirrhosis

荣誉历程

1986年中山医科大学毕业后在中山三院感染科从事肝病临床和科研工作37年，是全国规模最大的慢乙肝临床治愈“珠峰项目“主要参与者，为该项目入组和治愈慢乙肝患者最多的专家，临床治愈患者近200例
After graduating from Sun Yat- sen University of Medical Sciences in 1986, the physician spent 37 years conductingclinical and research work in hepatology at the Department of Infectious Diseases, the Third Affiliated Hospital of SunYat-sen University. The physician was a key participant in the "Mount Everest Project," China's largest nationwideclinical cure program for chronic hepatitis B, and was among the project's leading experts in patient enrollment andclinical cure, with nearly 200 patients achieving clinical cure under the physician's care

2022年担任超100家医院共同参与的全国多中心真实世界研究“容愈项目”(非活动性HBV感染者临床治愈项目)的项目负责人
In 2022, served as the principal investigator of the "Rongyu Project," a nationwide multicenter real-world study onclinical cure in individuals with inactive HBV infection, involving more than 100 hospitals

参与及主持多个国内外慢性乙型肝炎的抗病毒治疗新药的临床药物试验项目
Led and participated in multiple domestic and international clinical trials of novel antiviral therapies for chronichepatitis B